Felzartamab in Antibody-Mediated Rejection. Reply.
Publication
, Journal Article
Böhmig, GA; Patel, UD; Halloran, PF
Published in: N Engl J Med
September 26, 2024
Duke Scholars
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
September 26, 2024
Volume
391
Issue
12
Start / End Page
1162 / 1163
Location
United States
Related Subject Headings
- Humans
- Graft Rejection
- General & Internal Medicine
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Böhmig, G. A., Patel, U. D., & Halloran, P. F. (2024). Felzartamab in Antibody-Mediated Rejection. Reply. N Engl J Med, 391(12), 1162–1163. https://doi.org/10.1056/NEJMc2409970
Böhmig, Georg A., Uptal D. Patel, and Philip F. Halloran. “Felzartamab in Antibody-Mediated Rejection. Reply.” N Engl J Med 391, no. 12 (September 26, 2024): 1162–63. https://doi.org/10.1056/NEJMc2409970.
Böhmig GA, Patel UD, Halloran PF. Felzartamab in Antibody-Mediated Rejection. Reply. N Engl J Med. 2024 Sep 26;391(12):1162–3.
Böhmig, Georg A., et al. “Felzartamab in Antibody-Mediated Rejection. Reply.” N Engl J Med, vol. 391, no. 12, Sept. 2024, pp. 1162–63. Pubmed, doi:10.1056/NEJMc2409970.
Böhmig GA, Patel UD, Halloran PF. Felzartamab in Antibody-Mediated Rejection. Reply. N Engl J Med. 2024 Sep 26;391(12):1162–1163.
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
September 26, 2024
Volume
391
Issue
12
Start / End Page
1162 / 1163
Location
United States
Related Subject Headings
- Humans
- Graft Rejection
- General & Internal Medicine
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences